

Somatostatin Receptor Type 2 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/S8F66ACEF980EN.html>

Date: December 2019

Pages: 71

Price: US\$ 3,500.00 (Single User License)

ID: S8F66ACEF980EN

Abstracts

Somatostatin Receptor Type 2 - Pipeline Review, H2 2019

SUMMARY

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) pipeline Target constitutes close to 13 molecules. The latest report Somatostatin Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 6 and 2 respectively. Report covers products from therapy areas Hormonal Disorders, Oncology, Metabolic Disorders, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Acromegaly, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion (Cushing Disease), Pituitary Tumor, Gastric Motility Disorder, Hypoglycemia, Ileus (Intestinal Obstruction), Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma (Glomus Jugulare Tumor), Pheochromocytoma, Polycystic Kidney Disease, Type 2 Diabetes and Unspecified.

Furthermore, this report also reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development with respective active and

dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)

The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Overview

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in
Therapeutics Development

Amryt Pharma Plc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Enteris BioPharma Inc

GlyTech Inc

Ipsen SA

Progenics Pharmaceuticals Inc

Strongbridge Biopharma plc

Takeda Pharmaceutical Co Ltd

Tiburio Therapeutics Inc

Zucara Therapeutics Inc

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles

AP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRN-00808 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRN-01941 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Edotreotide Labeled Yttrium 90 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ianreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ianreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize SSTR2 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBR-760 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide IR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Products

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Product Development Milestones

Featured News & Press Releases

Oct 31, 2019: Ipsen presents data on Somatuline Autogel at ISPOR Europe 2019

Jul 12, 2019: Zucara Therapeutics secures grant from GlycoNet to expand and validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes

Jun 24, 2019: Ipsen announces U.S. FDA approval for newly designed pre-filled syringe for Somatuline Depot (lanreotide)

May 24, 2019: New investigational clinical data for Ipsens oncology products including lanreotide acetate in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting

May 24, 2019: Ipsen to present on Somatuline at 2019 ASCO Annual Meeting

May 21, 2019: Crinetics Pharmaceuticals initiates phase 1 study of CRN01941 for the treatment of neuroendocrine tumors

Mar 19, 2019: Crinetics Pharmaceuticals doses first patients in phase 2 clinical trials of CRN00808 for acromegaly

Mar 14, 2019: Crinetics Pharmaceuticals announces presentation on drug candidate CRN-00808 at ENDO2019

Mar 06, 2019: Ipsen to present improvements to Somatuline Autogel pre-filled syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

Feb 28, 2019: Ipsen to present new data on enhancement of patient care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

Oct 12, 2018: Ipsen to present data on Lanreotide at ESMO 2018

Oct 05, 2018: Ipsen presents data on Somatuline depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium

Jun 21, 2018: Crinetics Pharmaceuticals Awarded up to \$3.2 Million in SBIR Grants for Acromegaly

Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candidate CRN00808 at ENDO 2018

Feb 13, 2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amryt Pharma Plc, H2 2019
Pipeline by Crinetics Pharmaceuticals Inc, H2 2019
Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Pipeline by Enteris BioPharma Inc, H2 2019
Pipeline by GlyTech Inc, H2 2019
Pipeline by Ipsen SA, H2 2019
Pipeline by Progenics Pharmaceuticals Inc, H2 2019
Pipeline by Strongbridge Biopharma plc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Tiburio Therapeutics Inc, H2 2019
Pipeline by Zucara Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Amryt Pharma Plc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Enteris BioPharma Inc
GlyTech Inc
Ipsen SA
Progenics Pharmaceuticals Inc
Strongbridge Biopharma plc
Takeda Pharmaceutical Co Ltd
Tiburio Therapeutics Inc
Zucara Therapeutics Inc

I would like to order

Product name: Somatostatin Receptor Type 2 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/S8F66ACEF980EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S8F66ACEF980EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970